Clinical Trial Update: Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh [Phase 3]

View source ↗

Summary

A Phase III trial comparing a short-course combination therapy (Ambisome, Miltefosine, Paromomycin) to AmBisome for visceral leishmaniasis in Bangladesh has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)
• Miltefosine (miltefosine)
• Paromomycin (paromomycin)

Snippet

Sponsor: Drugs for Neglected Diseases | Conditions: Visceral Leishmaniasis | Phase 3 | Status: COMPLETED